Anti-ERCC1 antibody [8F1] (ab2356)
Key features and details
- Mouse monoclonal [8F1] to ERCC1
- Suitable for: ICC/IF, IHC-P, Flow Cyt
- Reacts with: Human
- Isotype: IgG2b
Overview
-
Product name
Anti-ERCC1 antibody [8F1]
See all ERCC1 primary antibodies -
Description
Mouse monoclonal [8F1] to ERCC1 -
Host species
Mouse -
Tested applications
Suitable for: ICC/IF, IHC-P, Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein corresponding to Human ERCC1.
-
Positive control
- Tonsil.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.3
Preservative: 0.05% Sodium azide
Constituent: 1% BSA -
Concentration information loading...
-
Purity
IgG fraction -
Clonality
Monoclonal -
Clone number
8F1 -
Myeloma
unknown -
Isotype
IgG2b -
Light chain type
unknown -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab2356 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC/IF |
Use a concentration of 1 µg/ml.
|
|
IHC-P |
1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
|
Flow Cyt |
Use 1µg for 106 cells.
ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody. |
Notes |
---|
ICC/IF
Use a concentration of 1 µg/ml. |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Flow Cyt
Use 1µg for 106 cells. ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody. |
Target
-
Function
Structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. -
Involvement in disease
Defects in ERCC1 are the cause of cerebro-oculo-facio-skeletal syndrome type 4 (COFS4) [MIM:610758]. COFS is a degenerative autosomal recessive disorder of prenatal onset affecting the brain, eye and spinal cord. After birth, it leads to brain atrophy, hypoplasia of the corpus callosum, hypotonia, cataracts, microcornea, optic atrophy, progressive joint contractures and growth failure. Facial dysmorphism is a constant feature. Abnormalities of the skull, eyes, limbs, heart and kidney also occur. -
Sequence similarities
Belongs to the ERCC1/RAD10/SWI10 family. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 2067 Human
- Omim: 126380 Human
- SwissProt: P07992 Human
- Unigene: 435981 Human
-
Alternative names
- COFS 4 antibody
- COFS4 antibody
- DNA excision repair protein ERCC 1 antibody
see all
Images
-
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human tonsil tissue with ab2356 labelling ERCC1.
-
ICC/IF image of ab2356 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab2356, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
-
Overlay histogram showing HeLa cells stained with ab2356 (red line). The cells were fixed with 100% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab2356, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.
-
Immunohistochemical analysis of formalin fixed paraffin embedded human tonsil tissue sections with ab2356 labelling ERCC1.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (28)
ab2356 has been referenced in 28 publications.
- Liu Z et al. Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer. Heliyon 8:e09643 (2022). PubMed: 35711974
- Yeh YS et al. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy. Pathol Oncol Res 26:1105-1116 (2020). PubMed: 31077069
- Huang MY et al. ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation. Oncol Lett 20:212 (2020). PubMed: 32963618
- Escalona RM et al. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells. BMC Cancer 20:960 (2020). PubMed: 33023532
- Kaira K et al. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Res 39:2483-2491 (2019). PubMed: 31092443